Review article: therapeutic aspects of bile acid signalling in the gut-liver axis.

"Declaration of personal interest : BS received travel support from AbbVie and Gilead, and was supported by an international research scholar by Gilead Sciences awarded to TR. MT received speaker fees from BMS, Falk Foundation, Gilead, Intercept and MSD; advisory board fees from Albireo, BiomX, Boehringer Ingelheim, Falk Pharma GmbH, Genfit, Gilead, Intercept, MSD, Novartis, Phenex, Regulus and Shire. He further received travel grants from Abbvie, Falk, Gilead and Intercept and unrestricted research grants from Albireo, Cymabay, Falk, Gilead, Intercept, MSD and Takeda. He is also coinventor of patents on the medical use of nor‐UDCA filed by the Medical Universities of Graz and Vienna. TR received grant support from Abbvie, Boehringer‐Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer‐Ingelheim, Gilead, MSD, Siemens; and travel support from Boehringer‐Ingelheim, Gilead and Roche."

"Funding information"